Drugs
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Drugs
Apr 28, 2024, 21:10 |
Drugs
Doug Rubinson: The best drug in GI cancers is 5-FU
Doug Rubinson, GI Medical Oncologist At Dana-Farber Cancer Centre, shared on X/Twitter: "In oncology, we…
Apr 28, 2024, 13:23 |
Drugs
Sam Blackman: US FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma
Sam Blackman, Co-founder and Chief Medical Officer of Day One Biopharmaceuticals, shared a post by Day…
Apr 28, 2024, 11:48 |
Drugs
Tovorafenib has now been approved for young patients with relapsed or progressive pediatric low-grade glioma - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute recently shared on LinkedIn: "For more than a decade, a collaborative team…
Apr 28, 2024, 06:07 |
Drugs
Lisa Lacasse: We are deeply disappointed that the White House is delaying to end the sale of menthol cigarettes
Lisa Lacasse, President of the American Cancer Society Cancer Action Network, shared a post on…
Apr 27, 2024, 11:36 |
Drugs
ASCO's Open Letter to Congress and the Administration To End Cancer Drug Shortages
The American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "Did you know…
Apr 26, 2024, 17:44 |
Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 26, 2024, 14:15 |
Drugs
Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker
Apr 26, 2024, 10:07 |
Drugs
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…
Apr 25, 2024, 21:06 |
Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Apr 25, 2024, 12:40 |
Drugs
Piotr Wysocki: Similar activity of topotecan and liposomal irinotecan in second-line treatment of SCLC
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
1
2
3
4
5
All:
305
Posts:
21 - 30
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube